Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302249 · ClinicalTrials.gov registry record · Phase 2
AR-12286 in Combination With Latanoprost
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT01302249 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT01302249, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
Interventions
- DRUG Latanoprost 0.005%
- DRUG AR-12286 Ophthalmic Solution 0.5%
- DRUG Timolol maleate ophthalmic solution 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302249
The ClinicalTrials.gov registry entry for NCT01302249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Latanoprost 0.005% is the first listed.
NCT01302249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302249 about?
NCT01302249 is a clinical study titled "AR-12286 in Combination With Latanoprost". This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
What is the current status of trial NCT01302249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2011-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01302249?
The interventions under investigation include: Latanoprost 0.005% (DRUG), AR-12286 Ophthalmic Solution 0.5% (DRUG), Timolol maleate ophthalmic solution 0.5% (DRUG).
Who is sponsoring clinical trial NCT01302249?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.